At the tested drug concentrations, 3-AB showed no significant cytostatic or cytotoxic effects, while olaparib generated cytostatic and no cytocidal effects against the BRCA1 mutated UWB1.289 and a lower cytostatic potential against the OVCAR-3 ovarian cancer cells. This evidence concerns the gene BRCA1 and ovarian carcinoma.